HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | N060613 | CASPER PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consulting Services, Inc FDA-2020-P-2004 · 3 docket documents Lachman Consulting Services, Inc. filed this citizen petition requesting that the FDA designate Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension/Drops approved under ANDA 064065 as a new Reference Standard in the Orange Book, because the current Reference Standard and Reference L | 505(q) | 2020-10-06 | Withdrawn | Lachman Consulting Services, Inc |
Citizen Petition from FOLEY & LARDNER LLP FDA-2020-P-1849 · 4 docket documents Foley & Lardner LLP filed this citizen petition under Section 505(j)(2)(C) of the FDC Act requesting that the FDA amend the Orange Book to designate Oticair Otic Suspension USP (ANDA A064065, held by Bausch and Lomb Pharmaceuticals Inc.) as an additional reference standard for CASPORYN HC Otic Suspe | 505(q) | 2020-09-03 | Withdrawn | FOLEY & LARDNER LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.83
per ml
Lowest NADAC/Unit
$3.83
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 64980044801NEOMYCIN-POLYMYXIN-HC EAR SUSP | $3.83 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.